Shanghai, China
CorrectSequence Therapeutics (Correctseq) is a clinical-stage biotech company innovating in the field of gene editing with its proprietary transformer Base Editor (tBE) technology, based in China since its founding in 2020. The company's slogan, "Correct the Gene, Brighten the Future," reflects its commitment to groundbreaking therapies for genetic diseases.
The lead candidate, CS-101, targets β-hemoglobinopathies with promising clinical results, including IND approval by the China NMPA. It shows potential for best-in-class status with effective outcomes in transfusion-dependent β-thalassemia and sickle cell disease (SCD). Meanwhile, CS-121 addresses hypertriglyceridemia using in vivo base editing delivered via lipid nanoparticles (LNP).
Backed by a CNY100.00M Series A investment from investors such as Lilly Asia Ventures and FuTeng Capital, Correctseq is poised for further development across biotech sectors like oncology and cardiovascular diseases, leveraging its tBE's capabilities in precise and efficient gene editing.
